TY - JOUR
T1 - Microbiota-based markers predictive of development of Clostridioides difficile infection
AU - Berkell, Matilda
AU - Mysara, Mohamed
AU - Xavier, Basil Britto
AU - van Werkhoven, Cornelis H.
AU - Monsieurs, Pieter
AU - Lammens, Christine
AU - Ducher, Annie
AU - Vehreschild, Maria J.G.T.
AU - Goossens, Herman
AU - de Gunzburg, Jean
AU - Bonten, Marc J.M.
AU - Malhotra-Kumar, Surbhi
AU - Engbers, Annemarie
AU - de Regt, Marieke
AU - Biehl, Lena M.
AU - Cornely, Oliver A.
AU - Jazmati, Nathalie
AU - Bouverne, Marie Noelle
AU - Sablier-Gallis, Frederique
AU - Mentré, France
AU - Merle, Uta
AU - Stallmach, Andreas
AU - Rupp, Jan
AU - Bogner, Johannes
AU - Lübbert, Christoph
AU - Silling, Gerda
AU - Witzke, Oliver
AU - Gikas, Achilleas
AU - Maraki, Sofia
AU - Daikos, George
AU - Tsiodras, Sotirios
AU - Skoutelis, Athanasios
AU - Sambatakou, Helen
AU - Pujol, Miquel
AU - Dominguez-Luzon, M. Angeles
AU - Aguado, Jose M.
AU - Bouza, Emilio
AU - Cobo, Javier
AU - Rodríguez-Baño, Jesús
AU - Almirante, Benito
AU - de la Torre Cisneros, Julian
AU - Florescu, Simin A.
AU - Nica, Maria
AU - Vata, Andrei
AU - Hristea, Adriana
AU - Lupse, Mihaela
AU - Herghea, Delia
AU - Postil, Deborah
AU - Barraud, Olivier
AU - Molina, Jean Michel
N1 - Funding Information:
C.H.v.W. received speaker fees from Pfizer and Merck/MSD, and non-financial research support from bioMérieux. A.D. is an employee and shareholder of Da Volterra. J.d.G. is a consultant and shareholder of Da Volterra. M.J.G.T.V. has received research grants from 3M, Astellas Pharma, Da Volterra, Gilead Sciences, Glycom, MaaT Pharma, Merck/MSD, Organobalance, Seres Therapeutics; speaker fees from Astellas Pharma, Basilea, Gilead Sciences, Merck/MSD, Organobalance, Pfizer and has been a consultant to Alb Fils Kliniken GmbH, Astellas Pharma, Da Volterra, Ferring, MaaT Pharma, Merck/MSD and Summit Therapeutics. M.B., M.M., B.B.X., C.L., P.M., M.J.M.B., H.G., S.M.-K. report no competing interests.
Funding Information:
This study was conducted on behalf of the ANTICIPATE study group (the full study group is available at the end of the manuscript) and has resulted in the filing of a European patent entitled “Prediction of clinical manifestations of gut microbiota dys-biosis”, application number EP19306720.4. This research project was supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU) under grant agreement no. 115523, Combatting Bacterial Resistance in Europe (COMBACTE), resources of which are composed of financial contribution from the European Union Seventh Framework Program (FP7/2007–2013) and Da Volterra, as a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) companies in kind and cash contribution. M.B. received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement no. 675412 awarded to H.G. S.M.-K. acknowledges funding as part of the Methusalem-Excellence consortium VAX-IDEA. We thank Prof. Amee Manges (University of British Columbia, Vancouver, Canada) for providing the validation dataset utilized in this study. The following reagent was obtained through BEI Resources, NIAID, NIH as part of the Human Microbiota Project: Genomic DNA from Microbial Mock Community B (Staggered, Low Concentration), v5.2L, for 16S rRNA Gene Sequencing, HM-783D.
Publisher Copyright:
© 2021, The Author(s).
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/4/14
Y1 - 2021/4/14
N2 - Antibiotic-induced modulation of the intestinal microbiota can lead to Clostridioides difficile infection (CDI), which is associated with considerable morbidity, mortality, and healthcare-costs globally. Therefore, identification of markers predictive of CDI could substantially contribute to guiding therapy and decreasing the infection burden. Here, we analyze the intestinal microbiota of hospitalized patients at increased CDI risk in a prospective, 90-day cohort-study before and after antibiotic treatment and at diarrhea onset. We show that patients developing CDI already exhibit significantly lower diversity before antibiotic treatment and a distinct microbiota enriched in Enterococcus and depleted of Ruminococcus, Blautia, Prevotella and Bifidobacterium compared to non-CDI patients. We find that antibiotic treatment-induced dysbiosis is class-specific with beta-lactams further increasing enterococcal abundance. Our findings, validated in an independent prospective patient cohort developing CDI, can be exploited to enrich for high-risk patients in prospective clinical trials, and to develop predictive microbiota-based diagnostics for management of patients at risk for CDI.
AB - Antibiotic-induced modulation of the intestinal microbiota can lead to Clostridioides difficile infection (CDI), which is associated with considerable morbidity, mortality, and healthcare-costs globally. Therefore, identification of markers predictive of CDI could substantially contribute to guiding therapy and decreasing the infection burden. Here, we analyze the intestinal microbiota of hospitalized patients at increased CDI risk in a prospective, 90-day cohort-study before and after antibiotic treatment and at diarrhea onset. We show that patients developing CDI already exhibit significantly lower diversity before antibiotic treatment and a distinct microbiota enriched in Enterococcus and depleted of Ruminococcus, Blautia, Prevotella and Bifidobacterium compared to non-CDI patients. We find that antibiotic treatment-induced dysbiosis is class-specific with beta-lactams further increasing enterococcal abundance. Our findings, validated in an independent prospective patient cohort developing CDI, can be exploited to enrich for high-risk patients in prospective clinical trials, and to develop predictive microbiota-based diagnostics for management of patients at risk for CDI.
KW - Aged
KW - Anti-Bacterial Agents/therapeutic use
KW - Bacteria/classification
KW - Biomarkers/analysis
KW - Clostridioides difficile/drug effects
KW - Clostridium Infections/diagnosis
KW - Female
KW - Gastrointestinal Microbiome
KW - Humans
KW - Male
KW - Middle Aged
KW - Prospective Studies
UR - http://www.scopus.com/inward/record.url?scp=85104488749&partnerID=8YFLogxK
U2 - 10.1038/s41467-021-22302-0
DO - 10.1038/s41467-021-22302-0
M3 - Article
C2 - 33854066
AN - SCOPUS:85104488749
SN - 2041-1723
VL - 12
SP - 1
EP - 14
JO - Nature Communications
JF - Nature Communications
IS - 4
M1 - 2241
ER -